DK1297851T3 - Inhibering af histondeacetylasesom behandling af hjertehypertrofi - Google Patents

Inhibering af histondeacetylasesom behandling af hjertehypertrofi

Info

Publication number
DK1297851T3
DK1297851T3 DK02021676T DK02021676T DK1297851T3 DK 1297851 T3 DK1297851 T3 DK 1297851T3 DK 02021676 T DK02021676 T DK 02021676T DK 02021676 T DK02021676 T DK 02021676T DK 1297851 T3 DK1297851 T3 DK 1297851T3
Authority
DK
Denmark
Prior art keywords
cardiac hypertrophy
inhibition
treatment
histone deacetylase
gene expression
Prior art date
Application number
DK02021676T
Other languages
English (en)
Inventor
Michael R Bristow
Carlin Long
Timothy A Mckinsey
Eric N Olson
Original Assignee
Univ Colorado
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado, Univ Texas filed Critical Univ Colorado
Application granted granted Critical
Publication of DK1297851T3 publication Critical patent/DK1297851T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK02021676T 2001-09-27 2002-09-27 Inhibering af histondeacetylasesom behandling af hjertehypertrofi DK1297851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US33404101P 2001-10-31 2001-10-31

Publications (1)

Publication Number Publication Date
DK1297851T3 true DK1297851T3 (da) 2005-05-30

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02021676T DK1297851T3 (da) 2001-09-27 2002-09-27 Inhibering af histondeacetylasesom behandling af hjertehypertrofi

Country Status (8)

Country Link
US (4) US6706686B2 (da)
EP (1) EP1297851B1 (da)
JP (2) JP2003238445A (da)
AT (1) ATE287731T1 (da)
DE (1) DE60202727T2 (da)
DK (1) DK1297851T3 (da)
ES (1) ES2236415T3 (da)
PT (1) PT1297851E (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541762A (ja) * 1998-11-10 2002-12-10 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｍｅｆ２転写因子の阻害による心肥大および心不全の予防方法
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
US20070104688A1 (en) * 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
EP2226072A1 (en) * 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2555632A1 (en) * 2004-02-02 2005-08-18 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
WO2005097088A2 (en) * 2004-04-05 2005-10-20 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005098425A1 (en) 2004-04-07 2005-10-20 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
EP3070174B1 (en) 2004-05-11 2019-11-06 Ncardia AG Drug discovery based on in vitro differentiated cells
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2596015A1 (en) 2005-02-14 2006-08-24 Sampath K. Anandan Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1901764A1 (en) * 2005-07-14 2008-03-26 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
BRPI0613429A2 (pt) * 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
EP1915141A1 (en) * 2005-08-10 2008-04-30 Novartis AG Method of use of deacetylase inhibitors
EP1962888A2 (en) * 2005-11-18 2008-09-03 Myogen, Inc. Uses for camkii and hdacs in the treatment of heart conditions
JP2009519224A (ja) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100226857A1 (en) * 2006-03-29 2010-09-09 Jeannine Strobl Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
CN101460197A (zh) * 2006-04-06 2009-06-17 诺瓦提斯公司 有机化合物的组合
US7696373B2 (en) * 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
WO2008013589A2 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2124990A4 (en) * 2006-12-29 2010-04-21 Gloucester Pharmaceuticals Inc TUMOR TREATMENT BASED ON ROMIDEPSIN
WO2008083288A2 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals Purifiction of romidepsin
US9884031B2 (en) * 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
WO2009048540A1 (en) * 2007-10-05 2009-04-16 U.S. Department Of Veterans Affairs Office Of General Counsel - Psg Iv (024) Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
US20100212036A1 (en) * 2008-09-30 2010-08-19 Olson Eric N Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
RU2607634C2 (ru) 2010-07-12 2017-01-10 Селджин Корпорейшн Твердые формы ромидепсина и их применение
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
JP6025732B2 (ja) 2010-10-13 2016-11-16 テトラロジック シェイプ ユーケイ エルティーディー ヒストンデアセチラーゼ阻害薬のための医薬製剤
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5968981A (en) * 1995-07-28 1999-10-19 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
ES2228119T3 (es) 1998-10-19 2005-04-01 Methylgene, Inc. Modulacion de la expresion de la adn-metil-tranferasa mediante terapia de combinacion.
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
EP1173562A2 (en) 1999-05-03 2002-01-23 Methylgene, Inc. Inhibition of histone deacetylase
US6632628B1 (en) 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017514A1 (en) * 1999-09-03 2001-03-15 The Salk Institute For Biological Studies Modulation of gene expression by modulating histone acetylation
JP2003508501A (ja) 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド 生物学的結合のための肺送達
ATE361316T1 (de) 1999-09-08 2007-05-15 Sloan Kettering Inst Cancer Kristallstruktur einer deacetylase und deren inhibitoren
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
CA2393725A1 (en) 1999-12-08 2001-06-14 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
WO2003006652A2 (en) 2000-03-24 2003-01-23 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
JP2004509941A (ja) 2000-09-29 2004-04-02 プロリフィクス　リミテッド Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US20040077046A1 (en) 2000-12-20 2004-04-22 Dalia Cohen Histone deacetylase-related gene and protein
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
US20040186049A1 (en) 2004-09-23
US20060069014A1 (en) 2006-03-30
PT1297851E (pt) 2005-06-30
US20060025333A1 (en) 2006-02-02
US6946441B2 (en) 2005-09-20
ATE287731T1 (de) 2005-02-15
DE60202727T2 (de) 2005-12-29
JP2010001311A (ja) 2010-01-07
EP1297851B1 (en) 2005-01-26
US20030144340A1 (en) 2003-07-31
ES2236415T3 (es) 2005-07-16
JP2003238445A (ja) 2003-08-27
EP1297851A1 (en) 2003-04-02
DE60202727D1 (de) 2005-03-03
US6706686B2 (en) 2004-03-16

Similar Documents

Publication Publication Date Title
DK1297851T3 (da) Inhibering af histondeacetylasesom behandling af hjertehypertrofi
DK1233958T3 (da) Hæmmere af histondeacetylase
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE463490T1 (de) Histondeacetylase-hemmer
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
DE69924135D1 (de) Heterozyklische kalium-kanal inhibitoren
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
MXPA04002397A (es) Inhibidores de histona deacetilasa.
PT1423391E (pt) Pirrolopirimidinas como agentes para a inibicao de proteases de cisteina
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200701782A3 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
DK1511472T3 (da) Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor
ATE443044T1 (de) Tace inhibitoren
EA200200948A1 (ru) Лечение псориаза
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
EA202190902A1 (ru) Ингибирование синтазы жирных кислот (fasn)